Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Cilta-Cel Provides Deep MRD Negativity in Lenalidomide-Refractory Multiple Myeloma

February 15th 2025

Cilta-cel led to rapid and deep MRD negativity in patients with lenalidomide-refractory multiple myeloma.

Joseph on the Effects of Resistance Training on Fatigue and Pain in Multiple Myeloma

February 14th 2025

Janine Joseph, MS, MBA, discusses the effects of resistance training interventions on fatigue and pain levels in patients with multiple myeloma.

P-BCMA-ALLO1 Is Safe and Efficacious in R/R Multiple Myeloma

February 14th 2025

P-BCMA-ALLO1 displayed early efficacy and safety data in relapsed/refractory multiple myeloma.

FDA Grants Orphan Drug Designation to OPN-6602 for R/R Multiple Myeloma

February 13th 2025

OPN-6602, a small molecule EP300/CBP inhibitor, received orphan drug designation for multiple myeloma.

FDA Accepts BLA Resubmission for Linvoseltamab in R/R Multiple Myeloma

February 11th 2025

A resubmitted biologics license application for linvoseltamab in relapsed/refractory multiple myeloma is under review by the FDA.

Weighing CAR T Toxicity Profiles in Early R/R MM

February 11th 2025

Panelists discuss how recent data from the KarMMa-3 study influence the decision to treat early-stage relapsed/refractory multiple myeloma (R/R MM) with idecabtagene vicleucel (ide-cel), as well as the key toxicities considered when selecting chimeric antigen receptor (CAR) T-cell therapy. They also explore how these toxicities impact the transition of patients back to the community setting post CAR T and share strategies for managing early- and late-stage toxicities.

CAR T in Early R/R MM: Advances in Ide-Cel From the KarMMa-3 Trial

February 11th 2025

Panelists discuss how recent data from the KarMMa-3 study inform the decision to treat early-stage relapsed/refractory multiple myeloma (R/R MM) with idecabtagene vicleucel (ide-cel), including insights from the updated analysis.

Five Under 5: Top Oncology Videos for the Week of 2/2

February 9th 2025

The top 5 videos of the week cover insights in lung cancer, multiple myeloma, breast cancer, and follicular lymphoma.

Dr Lin on Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma

February 7th 2025

Yi Lin, MD, PhD, discuses cilta-cel vs standard of care in patients with lenalidomide-refractory multiple myeloma.

Dr Phull on Real-World vs Trial Data for CAR T-Cell Therapy in R/R Multiple Myeloma

February 4th 2025

Pooja Phull, MD, highlights differences between real-world vs clinical trial data for cilta-cel vs ide-cel in relapsed/refractory multiple myeloma.

Quadruplet Regimens Stand Strong in Newly Diagnosed Multiple Myeloma

February 4th 2025

Experts break down emerging data for the use of quadruplet regimens in newly diagnosed multiple myeloma.

Cilta-Cel in Early R/R MM: Evolving CAR T Data from CARTITUDE-4

February 4th 2025

Panelists discuss the latest efficacy data from the CARTITUDE-4 study evaluating ciltacabtagene autoleucel (cilta-cel) in relapsed/refractory multiple myeloma (R/R MM), the significance of minimal residual disease (MRD) negativity, and how real-world and patient-reported outcomes influence the decision to use chimeric antigen receptor (CAR) T-cell therapy for early-stage R/R MM. They also compare standard-of-care idecabtagene vicleucel (ide-cel) and cilta-cel in this patient population.

Optimal Strategies for Bridging Therapy for Patients Receiving CAR T in Early R/R MM

February 4th 2025

Panelists discuss their optimal strategies for bridging therapy when preparing patients to receive chimeric antigen receptor (CAR) T in the treatment of relapsed/refractory multiple myeloma (R/R MM).

Dr Bishop on the Potential Significance of Anito-Cel for the Multiple Myeloma Treatment Paradigm

February 3rd 2025

Michael R. Bishop, MD, discusses the potential significance of anitocabtagene autoleucel for the relapsed/refractory multiple myeloma treatment paradigm.

Dr Landgren on Recent Treatment Paradigm Changes in Multiple Myeloma

February 3rd 2025

C. Ola Landgren, MD, PhD, discusses the rapidly changing treatment paradigm within multiple myeloma.

Five Under 5: Top Oncology Videos for the Week of 1/26

February 2nd 2025

The top 5 videos of the week cover insights in gastrointestinal cancers, gynecologic malignancies, and blood cancers.

China's NMPA Approves Isatuximab Plus VRd for Newly Diagnosed, Transplant-Ineligible Myeloma

January 31st 2025

China’s NMPA approved isatuximab plus VRd for newly diagnosed, transplant-ineligible multiple myeloma.

Real-World Analysis Shows Superior Efficacy With Cilta-Cel vs Ide-Cel in R/R Multiple Myeloma

January 31st 2025

Pooja Phull, MD, discusses real-world responses and survival outcomes with cilta-cel vs ide-cel in patients with relapsed/refractory multiple myeloma.

Dr Kaddoura on Challenges Integrating Whole Genome Sequencing Into Clinical Practice in Myeloma

January 30th 2025

Marcella Ali Kaddoura, MD, discusses challenges in integrating whole genome sequencing into routine clinical practice for myeloma.

Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)

January 30th 2025

Dr. Elias K. Mai presents final progression-free survival results from the Phase 3 GMMG-HD7 trial, demonstrating that adding isatuximab to lenalidomide, bortezomib, and dexamethasone (Isa-RVd) significantly improves minimal residual disease negativity and reduces the risk of progression or death in transplant-eligible patients with newly diagnosed multiple myeloma.